172 related articles for article (PubMed ID: 35698180)
41. IBD-related carcinoma and lymphoma.
Claessen MM; Siersema PD; Vleggaar FP
Best Pract Res Clin Gastroenterol; 2011 Apr; 25 Suppl 1():S27-38. PubMed ID: 21640928
[TBL] [Abstract][Full Text] [Related]
42. Clinical and molecular assessment of an onco-immune signature with prognostic significance in patients with colorectal cancer.
Ahluwalia P; Mondal AK; Ahluwalia M; Sahajpal NS; Jones K; Jilani Y; Gahlay GK; Barrett A; Kota V; Rojiani AM; Kolhe R
Cancer Med; 2022 Mar; 11(6):1573-1586. PubMed ID: 35137551
[TBL] [Abstract][Full Text] [Related]
43. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.
Khan M; Loree JM; Advani SM; Ning J; Li W; Pereira AAL; Lam M; Raghav K; Morris VK; Broaddus R; Maru D; Overman MJ; Kopetz S
Clin Colorectal Cancer; 2018 Dec; 17(4):e699-e709. PubMed ID: 30205948
[TBL] [Abstract][Full Text] [Related]
45. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
46. Construction of a novel methylation-related prognostic model for colorectal cancer based on microsatellite status.
Cao L; Chen E; Zhang H; Ba Y; Yan B; Li T; Yang J
J Cell Biochem; 2021 Dec; 122(12):1781-1790. PubMed ID: 34397105
[TBL] [Abstract][Full Text] [Related]
47. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
[TBL] [Abstract][Full Text] [Related]
48. Ferroptosis-related genes are potential prognostic molecular markers for patients with colorectal cancer.
Liu Y; Guo F; Guo W; Wang Y; Song W; Fu T
Clin Exp Med; 2021 Aug; 21(3):467-477. PubMed ID: 33674956
[TBL] [Abstract][Full Text] [Related]
49. Prognostic Signatures Based on Thirteen Immune-Related Genes in Colorectal Cancer.
Ma XB; Xu YY; Zhu MX; Wang L
Front Oncol; 2020; 10():591739. PubMed ID: 33680920
[TBL] [Abstract][Full Text] [Related]
50. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
51. Morphological, immunohistochemical and molecular features of inflammatory bowel disease associated colorectal carcinoma and associated mucosal lesions - Single institution experience.
Kamarádová K; Vošmiková H; Rozkošová K; Ryška A; Tachecí I; Laco J
Pathol Res Pract; 2019 Apr; 215(4):730-737. PubMed ID: 30679085
[TBL] [Abstract][Full Text] [Related]
52. Construction of a Novel Immune-Related mRNA Signature to Predict the Prognosis and Immune Characteristics of Human Colorectal Cancer.
Li J; Han T; Wang X; Wang Y; Chen X; Chen W; Yang Q
Front Genet; 2022; 13():851373. PubMed ID: 35401707
[No Abstract] [Full Text] [Related]
53. COL10A1 is a potential immunotherapy biomarker associated with immune infiltration and deficient mismatch repair in colon cancer.
Cai S; Sun Z; Yan Y; Li W; Wu Q
Immunotherapy; 2023 Oct; 15(15):1293-1308. PubMed ID: 37585671
[TBL] [Abstract][Full Text] [Related]
54. Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development.
Azer SA
Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):271-81. PubMed ID: 23169309
[TBL] [Abstract][Full Text] [Related]
55. NAT2 knockdown inhibits the development of colorectal cancer and its clinical significance.
Wang CL; Liu ZP; Guo L
Eur Rev Med Pharmacol Sci; 2021 May; 25(9):3460-3469. PubMed ID: 34002819
[TBL] [Abstract][Full Text] [Related]
56. Colorectal cancer in patients with inflammatory bowel disease: the true impact of the risk.
Herszényi L; Barabás L; Miheller P; Tulassay Z
Dig Dis; 2015; 33(1):52-7. PubMed ID: 25531497
[TBL] [Abstract][Full Text] [Related]
57. [m
Chen S; Dong R; Li Y; Wu H; Liu M
Nan Fang Yi Ke Da Xue Xue Bao; 2022 May; 42(5):681-689. PubMed ID: 35673911
[TBL] [Abstract][Full Text] [Related]
58. Clinical features, treatment, and survival of patients with colorectal cancer with or without inflammatory bowel disease.
Ali RA; Dooley C; Comber H; Newell J; Egan LJ
Clin Gastroenterol Hepatol; 2011 Jul; 9(7):584-9.e1-2. PubMed ID: 21565283
[TBL] [Abstract][Full Text] [Related]
59. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?
Dyson JK; Rutter MD
World J Gastroenterol; 2012 Aug; 18(29):3839-48. PubMed ID: 22876036
[TBL] [Abstract][Full Text] [Related]
60. Identification of biomarkers associated with diagnosis and prognosis of colorectal cancer patients based on integrated bioinformatics analysis.
Chen L; Lu D; Sun K; Xu Y; Hu P; Li X; Xu F
Gene; 2019 Apr; 692():119-125. PubMed ID: 30654001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
